Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific... – Synthetic polymer or copolymer
Reexamination Certificate
2006-08-08
2006-08-08
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
Synthetic polymer or copolymer
C424S201100, C424S203100, C424S184100, C424S234100, C424S253100, C424S254100, C514S002600, C530S825000, C530S350000
Reexamination Certificate
active
07087236
ABSTRACT:
A method of inducing either a TH1 polarized immune response, a TH2 polarized immune response or a combined TH1 and TH2 response to an antigen and associated vaccine formulations are disclosed. A method is provided for inducing a polarized TH1 response by parenteral administration of microparticles sized such that at least 50% of the microparticles are less than 5 μm. The microparticles containing antigen entrapped or encapsulated by a biodegradable polymer. Additionally, a method is provided for inducing a polarized TH2 response by parenteral administration of nanoparticles sized such that at least 50% of the nanoparticles are less than 600 nm, the nanoparticles containing antigen entrapped or encapsulated by a biodegradable polymer. Vaccine formulations containing theB. pertussisantigens PTd, FHA or a combination of PTd and FHA are provided.
REFERENCES:
patent: 5075109 (1991-12-01), Tice et al.
patent: 5362478 (1994-11-01), Desai et al.
patent: 5393527 (1995-02-01), Malick et al.
patent: 5417986 (1995-05-01), Reid et al.
patent: 5439686 (1995-08-01), Desai et al.
patent: 5441739 (1995-08-01), Kossovsky et al.
patent: 5529777 (1996-06-01), Andrianov et al.
patent: 5603960 (1997-02-01), O'Hagan et al.
patent: 5631263 (1997-05-01), Portoghese et al.
patent: 5674534 (1997-10-01), Zale et al.
patent: 5709879 (1998-01-01), Barchfeld et al.
patent: 5807757 (1998-09-01), Andrianov et al.
patent: 5871747 (1999-02-01), Gengoux-Sedlik et al.
patent: 5885586 (1999-03-01), Eckhardt et al.
patent: 5885587 (1999-03-01), Eckhardt et al.
patent: 5895655 (1999-04-01), Eckhardt et al.
patent: 5897867 (1999-04-01), Eckhardt et al.
patent: 6004763 (1999-12-01), Gengoux et al.
patent: 6024983 (2000-02-01), Tice et al.
patent: 6056964 (2000-05-01), Rook et al.
patent: 6309669 (2001-10-01), Setterstrom et al.
patent: 6372227 (2002-04-01), Garcon et al.
patent: 0 154 902 (1985-02-01), None
patent: 0 266 119 (1987-10-01), None
patent: 0 333 523 (1989-03-01), None
patent: 0 706 792 (1989-03-01), None
patent: 0 484 621 (1991-05-01), None
patent: 0 686 630 (1995-06-01), None
patent: 0 737 472 (1996-03-01), None
patent: WO 86/06635 (1986-11-01), None
patent: WO 90/04963 (1990-05-01), None
patent: WO 92/19263 (1992-11-01), None
patent: WO 93/20843 (1993-04-01), None
patent: WO 93/21950 (1993-11-01), None
patent: WO 94/06472 (1994-03-01), None
patent: WO 94/08588 (1994-04-01), None
patent: WO 94/09898 (1994-05-01), None
patent: WO 94/15636 (1994-07-01), None
patent: WO 94/21289 (1994-09-01), None
patent: WO 95/02416 (1995-01-01), None
patent: WO 95/11008 (1995-04-01), None
patent: WO 95/11010 (1995-04-01), None
patent: WO 95/13838 (1995-05-01), None
patent: WO 95/17167 (1995-06-01), None
patent: WO 95/28486 (1995-10-01), None
patent: WO 95/35097 (1995-12-01), None
patent: WO 96/14876 (1996-05-01), None
patent: WO 96/20698 (1996-07-01), None
patent: WO 97/17613 (1997-05-01), None
patent: WO 97/31691 (1997-09-01), None
patent: WO 97/32572 (1997-09-01), None
patent: WO 98/51325 (1998-11-01), None
patent: WO 98/51825 (1998-11-01), None
patent: WO 98/58668 (1998-12-01), None
Cahill et al. Vaccine 13: 455-462, 1995.
Shahin et al. Infect Immun. 63: 1195-1200, 1995.
Mills et al. Infect Immun. 61: 399-410, 1993.
Eldridge et al. J. Controlled Release 11: 205-214, 1990.
Moore et al. Vaccine 13: 1741-1749, 1995.
Nixon et al. Vaccine 14: 1523-1530, 1996.
Jones et al. Behring Inst. Mitt. 98: 220-228, Feb. 1997.
Jones et al. Vaccine 1: 675-681, 1995.
Maloy et al. Immunology 8: 661-667, 1994.
O'Hagan. In: New Generation of Vaccines, (Ed) M.M. Levine. Marcel Dekker Inc. Chapter 17, 2ndEdition, pp. 215-228, 1997.
Gregoriadis, G., “Preparation of Liposomes”, Liposome Technology, vol. 1, Clinical Research Centre, Middlesex, England, pp. 122-129.
Ostro, M.J., “Liposomes”, From Biophysics to Therapeutics, The Liposome Company, Princeton, New Jersey, pp. 73-108.
Rechtman, D., “Oral Administration of Tetanus Vaccine—Issues Related to Acceptance, Target Populations and Clinical Trials”, PharmaMedical Consultants International, pp. 1-11.
Preis, I. et al., “A Single-Step Immunization by Sustained Antigen Release”, J. Immunol Methods, vol. 28, No. 1-2, 1979, pp. 193-197.
Uchida et al , “Oral Delivery of Poly(lactide-co-glycolide) Microspheres Containing Ovalbumin as Vaccine Formulation: Particle Size Study” Biol. Pharm. Bull., vol. 17, No. 9, Sep. 1994, pp. 1272-1276.
Maloy, K. et al., “Induction of Mucosal and Systemic Immune Responses by Immunization with Ovalbumin Entrapped in Poly(lactide-co-glycolide) Microparticles”, Immunology, vol. 81, 1994, pp. 661-667.
Ulrich, J. et al., “Monophosphoryl Lipid A as an Adjuvant—Past Experiences and New Directions”, Ribi ImmunoChem Research, Inc., Hamilton, Montana 59840, Chapter 21, pp. 495-523, 1995.
Moore, A. et al., “Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+cytotoxic T lymphocytes and CD4+Th1 cells”, Vaccine, vol. 18, Oct. 29, 1995, pp. 1-11.
Men, Y. et al., “A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide”, Vaccine, vol. 13, No. 7, 1995, pp. 683-689.
Desai, M.P. et al., “Gastrointestinal uptake of biodegradable microparticles: effect of particle size”, Pharmaceutical Research, vol. 13, No. 12, 1996, pp. 1838-1845.
Marinaro, M. et al., “Use of Intranals IL-12 to Target Predominantly Th1 Responses to Nasal and Th2 Responses to Oral Vaccines Given with Cholera Toxin1”, The Journal of Immunology, 1999, pp. 114-121.
Jones, D.H. et al., “Orally Administered MicroencapsulatedBordetella pertussisFimbriae Protect Mice fromB. pertussisRespiratory Infection”, Infection and Immunity, vol. 64, No. 2, Feb. 1996, pp. 489-494.
Lee, V., “Pharmaceutical Research”, An Official Journal of the American Association of Pharmaceutical Scientists, vol. 13, No. 9, Sep. 1996, pp. S237-S242.
Rubas, W. et al., “An Integrated Method to Determine Epithelial Transport and Bioactivity of Oral Drug Candidates in Vitro”, Pharmaceutical Research, vol. 13, No. 1, 1996, pp. 23-25.
McClean, S. et al., “Binding and Uptake of Biodegradable Poly-DL-Lactide Micro- and Nanoparticles in Intestinal Epithelia”, European Journal of Pharmaceutical Sciences, 1997, pp. 3-11.
Nugent, J. et al., “Design and delivery of non-parenteral vaccines”, Journal of Clinical Pharmacy and Therapeutics, vol. 23, No. 4, Aug. 1998, pp. 257-285.
Brayden, D.J., et al., “Novel oral drug delivery gateways for biotechnology products: polypeptides and vaccines”. Pharmaceuticals Science and Technology Today, vol. 1, No. 7, Oct. 1998 pp. 291-299.
Singh, et al., “The preparation and characterization of polymeric antigen delivery systems for oral administration”. Adv. Drug Delivery Rev, Dec. 1998, vol. 34, No. 2-3, pp. 285-304.
Singh, et al., “Controlled release microparticles as a single dose diphtheria toxoid vaccine: immunogenicity in small animal models”, Vaccine, Feb. 1998, vol. 16, No. 4, 1998, pp. 346-352.
Newman, K. et al., “Delivery of MUC1 Mucin Peptide by Poly(d,l-lactic-co-glycolic acid) Microspheres Induces Type 1 T Helper Immune Responses”, Journal of Pharmaceutical Sciences, vol. 87, No. 11, Nov. 1998, pp. 1421-1428.
Harokopakis, E. et al., “Effectiveness of Liposomes Possessing Surface-Linked Recombinant B Subunit of Cholera Toxin as an Oral Antigen Delivery System”, Infection and Immunity, Sep. 1998, vol. 66, No. 9, pp. 4299-4304.
Croyle, M. et al., “In-Vitro and in-Vivo Assessment of Adenovirus 41 as a vector for gene delivery to the intestine”, Gene Therapy, vol. 5, 1998, pp. 645-654.
Rook, G. et al., “Give Us This Day our Daily Germs”, Immunology Today, vol. 19, No. 3, Mar. 1998, pp. 113-120.
Ryan, M. et al., &#
Devi S.
Merrion Research I Limited
Synnestvedt & Lechner LLP
LandOfFree
Method for inducing a cell-mediated immune response and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inducing a cell-mediated immune response and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inducing a cell-mediated immune response and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3717107